[{"id":"e1eec305-12a1-4b55-aca1-9621bccaf5e0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05836324","created_at":"2023-05-01T15:04:34.613Z","updated_at":"2025-02-25T14:03:30.395Z","phase":"Phase 1","brief_title":"A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT05836324","lead_sponsor":"Incyte Corporation","biomarkers":" HER-2 • BRAF • ER • PGR • ROS1","pipe":" | ","alterations":" HER-2 negative • ER negative","tags":["HER-2 • BRAF • ER • PGR • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e INCA33890"],"overall_status":"Recruiting","enrollment":" Enrollment 245","initiation":"Initiation: 07/24/2023","start_date":" 07/24/2023","primary_txt":" Primary completion: 12/24/2026","primary_completion_date":" 12/24/2026","study_txt":" Completion: 12/24/2026","study_completion_date":" 12/24/2026","last_update_posted":"2025-02-19"},{"id":"eef00741-67ea-4f6a-a30f-9aebbb089fa9","acronym":"NeoVAB","url":"https://clinicaltrials.gov/study/NCT03876951","created_at":"2021-01-18T19:06:42.497Z","updated_at":"2025-02-25T14:07:21.577Z","phase":"","brief_title":"Evaluation of the Accuracy of Percutaneous Biopsy by Vacuum-assisted Biopsy (VAB) to Assess Pathological Complete Response in Patients With Clinical and Radiological Complete Response After Neoadjuvant Chemotherapy (NeoVAB)","source_id_and_acronym":"NCT03876951 - NeoVAB","lead_sponsor":"Centre Georges Francois Leclerc","biomarkers":" ER","pipe":" | ","alterations":" HER-2 positive • ER positive • ER negative","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • ER positive • ER negative"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 67","initiation":"Initiation: 08/30/2019","start_date":" 08/30/2019","primary_txt":" Primary completion: 02/28/2025","primary_completion_date":" 02/28/2025","study_txt":" Completion: 04/08/2025","study_completion_date":" 04/08/2025","last_update_posted":"2025-02-17"},{"id":"33ba8dc4-62a4-4720-a240-ae4cca294bb8","acronym":"","url":"https://clinicaltrials.gov/study/NCT04677816","created_at":"2021-01-19T20:46:03.224Z","updated_at":"2025-02-25T15:18:57.775Z","phase":"Phase 2","brief_title":"Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients","source_id_and_acronym":"NCT04677816","lead_sponsor":"Wake Forest University Health Sciences","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 negative • ER negative","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • doxorubicin hydrochloride • cyclophosphamide"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 10/22/2021","start_date":" 10/22/2021","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2025-02-12"},{"id":"99f591b9-7e23-4ea7-a5a0-fe1e2287e1db","acronym":"KEYNOTE-F21","url":"https://clinicaltrials.gov/study/NCT04225117","created_at":"2021-01-18T20:34:06.535Z","updated_at":"2025-02-25T15:18:27.870Z","phase":"Phase 2","brief_title":"A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)","source_id_and_acronym":"NCT04225117 - KEYNOTE-F21","lead_sponsor":"Astellas Pharma Global Development, Inc.","biomarkers":" BRAF • ER • ALK • PGR","pipe":" | ","alterations":" PD-L1 expression • HER-2 positive • ER positive • EGFR mutation • BRAF mutation • HER-2 negative • ER negative • HER-2 negative + ER positive","tags":["BRAF • ER • ALK • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 positive • ER positive • EGFR mutation • BRAF mutation • HER-2 negative • ER negative • HER-2 negative + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Padcev (enfortumab vedotin-ejfv)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 329","initiation":"Initiation: 03/09/2020","start_date":" 03/09/2020","primary_txt":" Primary completion: 09/30/2026","primary_completion_date":" 09/30/2026","study_txt":" Completion: 09/30/2026","study_completion_date":" 09/30/2026","last_update_posted":"2025-02-12"},{"id":"e94eda48-02c6-40bc-8f38-bdeb553754b5","acronym":"CASE6119","url":"https://clinicaltrials.gov/study/NCT04674306","created_at":"2021-01-19T20:45:27.933Z","updated_at":"2025-02-25T15:18:56.819Z","phase":"Phase 1","brief_title":"Adjuvant Therapy with an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer","source_id_and_acronym":"NCT04674306 - CASE6119","lead_sponsor":"George T. Budd","biomarkers":" HER-2 • ER • PGR • BRCA1 • PRL","pipe":" | ","alterations":" HER-2 negative • PALB2 mutation • ER negative","tags":["HER-2 • ER • PGR • BRCA1 • PRL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PALB2 mutation • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e alpha-lactalbumin vaccine"],"overall_status":"Recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 10/01/2021","start_date":" 10/01/2021","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2025-02-12"},{"id":"b1b80856-36d7-4b3b-b80b-159943ef72f4","acronym":"","url":"https://clinicaltrials.gov/study/NCT04329065","created_at":"2021-01-18T20:58:01.125Z","updated_at":"2025-02-25T16:44:52.494Z","phase":"Phase 2","brief_title":"Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer","source_id_and_acronym":"NCT04329065","lead_sponsor":"University of Washington","biomarkers":" HER-2 • ER • PGR • CD4","pipe":" | ","alterations":" ER negative • PGR negative","tags":["HER-2 • ER • PGR • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER negative • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • paclitaxel • Perjeta (pertuzumab) • Herzuma (trastuzumab-pkrb) • Ontruzant (trastuzumab-dttb) • Ogivri (trastuzumab-dkst) • Trazimera (trastuzumab-qyyp) • Herwenda (trastuzumab biosimilar) • EG1206A (pertuzumab biosimilar) • SIBP-01 (trastuzumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 16","initiation":"Initiation: 04/20/2022","start_date":" 04/20/2022","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2027","study_completion_date":" 06/30/2027","last_update_posted":"2025-02-06"},{"id":"70895122-f43e-478e-b06c-44c96910d6ec","acronym":"","url":"https://clinicaltrials.gov/study/NCT04265872","created_at":"2021-04-20T09:53:17.764Z","updated_at":"2025-02-25T16:44:48.890Z","phase":"Phase 1","brief_title":"Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC","source_id_and_acronym":"NCT04265872","lead_sponsor":"Baylor Research Institute","biomarkers":" ER • HRD","pipe":" | ","alterations":" HRD • ER negative","tags":["ER • HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • bortezomib"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 10/15/2020","start_date":" 10/15/2020","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 03/31/2026","study_completion_date":" 03/31/2026","last_update_posted":"2025-02-05"},{"id":"970c6f47-72fa-4370-9067-ddab6a5a704f","acronym":"SYNERGY","url":"https://clinicaltrials.gov/study/NCT03616886","created_at":"2021-01-18T17:46:20.617Z","updated_at":"2025-02-25T15:07:48.966Z","phase":"Phase 1/2","brief_title":"Paclitaxel + Carboplatin + Durvalumab With or Without Oleclumab for Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC","source_id_and_acronym":"NCT03616886 - SYNERGY","lead_sponsor":"Jules Bordet Institute","biomarkers":" HER-2 • ER • PGR • CD73","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 negative • ER negative","tags":["HER-2 • ER • PGR • CD73"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 negative • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Imfinzi (durvalumab) • paclitaxel • oleclumab (MEDI9447)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 129","initiation":"Initiation: 12/28/2018","start_date":" 12/28/2018","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-12-19"},{"id":"3554ca16-61bd-4047-833c-b83d03ee0735","acronym":"","url":"https://clinicaltrials.gov/study/NCT06038539","created_at":"2023-09-15T18:09:54.550Z","updated_at":"2025-02-25T13:55:34.751Z","phase":"Phase 3","brief_title":"Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer","source_id_and_acronym":"NCT06038539","lead_sponsor":"Biocon Biologics UK Ltd","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 overexpression • ER negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • docetaxel • Perjeta (pertuzumab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 382","initiation":"Initiation: 01/31/2025","start_date":" 01/31/2025","primary_txt":" Primary completion: 03/15/2026","primary_completion_date":" 03/15/2026","study_txt":" Completion: 11/15/2026","study_completion_date":" 11/15/2026","last_update_posted":"2024-12-17"},{"id":"647b1a25-385e-4dd4-87ce-8fee2a316c5b","acronym":"PM8002-B004C-TNBC-R","url":"https://clinicaltrials.gov/study/NCT05918133","created_at":"2023-06-26T14:09:06.723Z","updated_at":"2025-02-25T16:27:29.863Z","phase":"Phase 1/2","brief_title":"A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC","source_id_and_acronym":"NCT05918133 - PM8002-B004C-TNBC-R","lead_sponsor":"Biotheus Inc.","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 negative • ER negative","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • pumitamig (BNT327)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 07/01/2022","start_date":" 07/01/2022","primary_txt":" Primary completion: 10/30/2026","primary_completion_date":" 10/30/2026","study_txt":" Completion: 10/30/2026","study_completion_date":" 10/30/2026","last_update_posted":"2024-12-03"},{"id":"23bb9de1-3af9-4aa6-8cce-545836191b15","acronym":"IMpassion050","url":"https://clinicaltrials.gov/study/NCT03726879","created_at":"2021-01-18T18:15:43.055Z","updated_at":"2025-02-25T13:52:41.144Z","phase":"Phase 3","brief_title":"A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer","source_id_and_acronym":"NCT03726879 - IMpassion050","lead_sponsor":"Hoffmann-La Roche","biomarkers":" HER-2 • PD-L1 • ER • PGR","pipe":" | ","alterations":" PD-L1 expression • HER-2 positive • ER negative","tags":["HER-2 • PD-L1 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 positive • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Tecentriq (atezolizumab) • paclitaxel • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • doxorubicin hydrochloride • cyclophosphamide • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 454","initiation":"Initiation: 01/11/2019","start_date":" 01/11/2019","primary_txt":" Primary completion: 02/05/2021","primary_completion_date":" 02/05/2021","study_txt":" Completion: 08/24/2023","study_completion_date":" 08/24/2023","last_update_posted":"2024-11-05"},{"id":"8cf55ab0-20f6-44cb-8bda-ecaebf4b0cba","acronym":"I-SPY 2","url":"https://clinicaltrials.gov/study/NCT01042379","created_at":"2021-01-17T17:27:23.313Z","updated_at":"2025-02-25T12:25:36.876Z","phase":"Phase 2","brief_title":"I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer","source_id_and_acronym":"NCT01042379 - I-SPY 2","lead_sponsor":"QuantumLeap Healthcare Collaborative","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • ER negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • carboplatin • Imfinzi (durvalumab) • paclitaxel • Nerlynx (neratinib) • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • doxorubicin hydrochloride • Talzenna (talazoparib) • Verzenio (abemaciclib) • Zejula (niraparib) • cyclophosphamide • irinotecan • Jemperli (dostarlimab-gxly) • Tukysa (tucatinib) • letrozole • veliparib (ABT-888) • Libtayo (cemiplimab-rwlc) • MK-2206 • Datroway (datopotamab deruxtecan-dlnk) • Ziihera (zanidatamab-hrii) • ganitumab (AMG 479) • amcenestrant (SAR439859) • anvatabart opadotin (JNJ-0683) • metformin • Jivadco (trastuzumab duocarmazine) • Turalio (pexidartinib) • ganetespib (ADX-1612) • vepdegestrant (ARV-471) • Cosela (trilaciclib) • Fablyn (lasofoxifene) • DAN-222 • fianlimab (REGN3767) • Oraxol (oral paclitaxel/encequidar) • ladiratuzumab vedotin (SGN-LIV1A) • nelitolimod (SD-101) • patritumab (U3-1287) • rilvegostomig (AZD2936) • trebananib (AMG 386) • Kevzara (sarilumab) • Voyager-V1"],"overall_status":"Recruiting","enrollment":" Enrollment 5000","initiation":"Initiation: 03/01/2010","start_date":" 03/01/2010","primary_txt":" Primary completion: 12/01/2030","primary_completion_date":" 12/01/2030","study_txt":" Completion: 12/01/2031","study_completion_date":" 12/01/2031","last_update_posted":"2024-10-22"},{"id":"3f4801d6-52e8-46ea-a4ce-c058e7891e0e","acronym":"","url":"https://clinicaltrials.gov/study/NCT02187991","created_at":"2021-01-18T10:12:40.272Z","updated_at":"2025-02-25T14:57:00.891Z","phase":"Phase 2","brief_title":"Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer","source_id_and_acronym":"NCT02187991","lead_sponsor":"US Oncology Research","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative • ER negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • alisertib (MLN8237)"],"overall_status":"Completed","enrollment":" Enrollment 169","initiation":"Initiation: 02/12/2015","start_date":" 02/12/2015","primary_txt":" Primary completion: 04/11/2024","primary_completion_date":" 04/11/2024","study_txt":" Completion: 08/01/2024","study_completion_date":" 08/01/2024","last_update_posted":"2024-10-09"},{"id":"600fe2c1-8174-4610-9b08-169ca63b195f","acronym":"DESTINY-Breast05","url":"https://clinicaltrials.gov/study/NCT04622319","created_at":"2021-01-19T20:34:44.181Z","updated_at":"2025-02-25T14:59:28.771Z","phase":"Phase 3","brief_title":"A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)","source_id_and_acronym":"NCT04622319 - DESTINY-Breast05","lead_sponsor":"Daiichi Sankyo","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 expression • ER negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 expression • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kadcyla (ado-trastuzumab emtansine) • Enhertu (fam-trastuzumab deruxtecan-nxki)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1600","initiation":"Initiation: 12/04/2020","start_date":" 12/04/2020","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2030","study_completion_date":" 12/31/2030","last_update_posted":"2024-10-09"},{"id":"677800b2-65d4-4839-8d33-a8d6a268ca72","acronym":"STOP-HER2","url":"https://clinicaltrials.gov/study/NCT05721248","created_at":"2023-02-09T15:00:23.584Z","updated_at":"2025-02-25T13:54:55.452Z","phase":"Phase 2","brief_title":"STOP-HER2: Stopping Trastuzumab in HER2+ MBC","source_id_and_acronym":"NCT05721248 - STOP-HER2","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" ER","pipe":" | ","alterations":" HER-2 positive • ER positive • HER-2 negative • ER negative • HER-2 negative + ER positive","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • ER positive • HER-2 negative • ER negative • HER-2 negative + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Perjeta (pertuzumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 82","initiation":"Initiation: 04/19/2023","start_date":" 04/19/2023","primary_txt":" Primary completion: 02/01/2026","primary_completion_date":" 02/01/2026","study_txt":" Completion: 02/01/2036","study_completion_date":" 02/01/2036","last_update_posted":"2024-09-30"},{"id":"4b76673c-cd8f-4b3e-aab1-a119e574fcaa","acronym":"MASTERKEY318","url":"https://clinicaltrials.gov/study/NCT02509507","created_at":"2021-01-18T12:07:01.792Z","updated_at":"2025-02-25T16:14:58.621Z","phase":"Phase 1/2","brief_title":"Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611","source_id_and_acronym":"NCT02509507 - MASTERKEY318","lead_sponsor":"Amgen","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HR positive • ER negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HR positive • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Imlygic (talimogene laherparepvec)"],"overall_status":"Completed","enrollment":" Enrollment 127","initiation":"Initiation: 02/05/2016","start_date":" 02/05/2016","primary_txt":" Primary completion: 02/14/2022","primary_completion_date":" 02/14/2022","study_txt":" Completion: 07/11/2023","study_completion_date":" 07/11/2023","last_update_posted":"2024-08-06"},{"id":"8b40b8c5-f34a-4144-9db3-f4f7a7d1b177","acronym":"","url":"https://clinicaltrials.gov/study/NCT01471106","created_at":"2021-01-18T06:07:51.037Z","updated_at":"2025-02-25T14:33:09.458Z","phase":"Phase 2","brief_title":"Phase II Short-term Adjuvant Therapy and Biomarker Studies With Targeted Agents in Women With Estrogen Receptor Negative Breast Cancer","source_id_and_acronym":"NCT01471106","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ER","pipe":" | ","alterations":" ER negative","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib"],"overall_status":"Completed","enrollment":" Enrollment 26","initiation":"Initiation: 01/21/2014","start_date":" 01/21/2014","primary_txt":" Primary completion: 01/31/2024","primary_completion_date":" 01/31/2024","study_txt":" Completion: 05/30/2024","study_completion_date":" 05/30/2024","last_update_posted":"2024-07-10"},{"id":"c6eb5752-3b02-4b81-89d4-72c52d5a889a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04090398","created_at":"2021-01-18T20:01:06.898Z","updated_at":"2024-07-02T16:34:58.839Z","phase":"Phase 2","brief_title":"Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones","source_id_and_acronym":"NCT04090398","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HR positive • HER-2 negative • ER negative • PGR negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HR positive • HER-2 negative • ER negative • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • Xofigo (radium Ra-223 dichloride)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 08/04/2020","start_date":" 08/04/2020","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-06-05"},{"id":"9a4a0bc7-29e9-4342-9fd2-fda5ba18ef80","acronym":"NRG-BR003","url":"https://clinicaltrials.gov/study/NCT02488967","created_at":"2021-01-18T11:59:46.930Z","updated_at":"2024-07-02T16:34:59.476Z","phase":"Phase 3","brief_title":"Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer","source_id_and_acronym":"NCT02488967 - NRG-BR003","lead_sponsor":"NRG Oncology","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative • ER negative • PGR negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • ER negative • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • doxorubicin hydrochloride • cyclophosphamide • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 782","initiation":"Initiation: 07/26/2015","start_date":" 07/26/2015","primary_txt":" Primary completion: 10/31/2026","primary_completion_date":" 10/31/2026","study_txt":" Completion: 10/31/2026","study_completion_date":" 10/31/2026","last_update_posted":"2024-06-03"},{"id":"e5aa0f89-24de-40bf-8a67-186c3db1a88b","acronym":"ARC-2","url":"https://clinicaltrials.gov/study/NCT03719326","created_at":"2021-01-18T18:13:45.819Z","updated_at":"2024-07-02T16:35:01.152Z","phase":"Phase 1","brief_title":"A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies","source_id_and_acronym":"NCT03719326 - ARC-2","lead_sponsor":"Arcus Biosciences, Inc.","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative • ER negative • PGR negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • ER negative • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • pegylated liposomal doxorubicin • eganelisib (IPI-549) • etrumadenant (AB928) • doxorubicin liposomal"],"overall_status":"Completed","enrollment":" Enrollment 35","initiation":"Initiation: 10/15/2018","start_date":" 10/15/2018","primary_txt":" Primary completion: 07/01/2021","primary_completion_date":" 07/01/2021","study_txt":" Completion: 07/02/2021","study_completion_date":" 07/02/2021","last_update_posted":"2024-05-24"},{"id":"9a957162-f9ec-4d41-9b25-cad512d70cf0","acronym":"","url":"https://clinicaltrials.gov/study/NCT02295059","created_at":"2021-01-18T10:49:15.244Z","updated_at":"2024-07-02T16:35:01.286Z","phase":"","brief_title":"Omega 3 Fatty Acids and ERPR(-)HER2(+/-) Breast Cancer Prevention","source_id_and_acronym":"NCT02295059","lead_sponsor":"City of Hope Medical Center","biomarkers":" ER • PGR","pipe":" | ","alterations":" ER negative • PGR negative","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER negative • PGR negative"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 08/09/2017","start_date":" 08/09/2017","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2024-05-23"},{"id":"c0f6572e-e0b9-41ba-be48-0dac251b1d1a","acronym":"A011801","url":"https://clinicaltrials.gov/study/NCT04457596","created_at":"2021-01-18T21:26:12.793Z","updated_at":"2024-07-02T16:35:01.275Z","phase":"Phase 3","brief_title":"T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial","source_id_and_acronym":"NCT04457596 - A011801","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" ER • PGR","pipe":" | ","alterations":" HER-2 positive • ER positive • HR positive • HR negative • ER negative","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • ER positive • HR positive • HR negative • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Kadcyla (ado-trastuzumab emtansine) • Tukysa (tucatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 1031","initiation":"Initiation: 01/06/2021","start_date":" 01/06/2021","primary_txt":" Primary completion: 01/01/2028","primary_completion_date":" 01/01/2028","study_txt":" Completion: 05/01/2035","study_completion_date":" 05/01/2035","last_update_posted":"2024-05-23"},{"id":"641e1e85-802d-456b-8ede-12ae69c97226","acronym":"NeoTENNIS","url":"https://clinicaltrials.gov/study/NCT04418154","created_at":"2021-01-18T21:17:40.275Z","updated_at":"2024-07-02T16:35:02.194Z","phase":"Phase 2","brief_title":"Neoadjuvant Dose-dense EC Followed by ABX With PD-1 for Triple Negative Breast Cancer Patients","source_id_and_acronym":"NCT04418154 - NeoTENNIS","lead_sponsor":"Fudan University","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative • ER negative • PGR negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • ER negative • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • albumin-bound paclitaxel • cyclophosphamide • epirubicin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 06/09/2020","start_date":" 06/09/2020","primary_txt":" Primary completion: 09/28/2022","primary_completion_date":" 09/28/2022","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-05-21"},{"id":"c32f89f3-a298-4176-84bb-cec4e2a46e3a","acronym":"","url":"https://clinicaltrials.gov/study/NCT02398773","created_at":"2021-01-18T11:26:39.322Z","updated_at":"2024-07-02T16:35:02.895Z","phase":"Phase 2","brief_title":"FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy","source_id_and_acronym":"NCT02398773","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ER • PGR","pipe":" | ","alterations":" ER negative • PGR positive • PGR negative","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER negative • PGR positive • PGR negative"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 99","initiation":"Initiation: 05/04/2016","start_date":" 05/04/2016","primary_txt":" Primary completion: 04/04/2025","primary_completion_date":" 04/04/2025","study_txt":" Completion: 04/04/2025","study_completion_date":" 04/04/2025","last_update_posted":"2024-05-17"}]